Endothelial Function and Heart Rate Variability After Stenting (FUNKIS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to evaluate whether impaired endothelial function and low heart rate variability are associated with clinical restenosis after percutaneous coronary intervention with stent implantation in patients with angina or acute coronary syndrome.
Furthermore, the study examines a potential correlation between biomarkers of endothelial cell activation and endothelial dysfunction.
| Condition | Intervention |
|---|---|
|
Restenosis or Adverse Cardiovascular Event |
Device: stent implantation in coronary artery |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Endothelial Function and Heart Rate Variability After Stenting in Coronary Arteries |
- clinical restenosis, major cardiovascular event [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- endothelial function, heart rate variability [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
serum, plasma and full blood
| Enrollment: | 100 |
| Study Start Date: | July 2007 |
| Study Completion Date: | October 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
coronary artery disease
patients who have been revascularized by PCI with stent implantation due to an acute coronary syndrome
|
Device: stent implantation in coronary artery
Percuatenous Coronary Intervention with implanatation of a stent
|
Detailed Description:
Background Atherosclerosis is a chronic, systemic and diffusely distributed disease causing focal complications in different vascular beds.
Impaired endothelial function is the initial step in the progressive course of atherosclerosis . Endothelial dysfunction is considered a systemic process and both coronary and peripheral endothelial dysfunction have been shown to be independently associated with cardiovascular events .
Percutanenous coronary intervention (PCI) with implantation of stent is the treatment of choice in symptomatic stenotic coronary artyery disease (CAD), but in-stent restenosis and progression of disease remains its main limitation. Early identification of patients at risk of restenosis after PCI would therefore be of clinical value. There is only limited prospective data on the role of peripheral endothelial dysfunction after PCI predicting restenosis and cardiovascular events , , .
Furthermore, it is unknown if peripheral endothelial dysfunction is associated with increased levels of biomarkers of endothelial cell activation in this population.
There are conflicting data on inflammatory markers as high-sensitivity CRP with regard to endothelial function.
Low heart rate variability (HRV) predicts automic dysfunction and is a strong and independent predictor of mortality in patients with coronary artery disease (CAD) . Clinical depression after myocardial infarction is associated with decreased HRV, linking depression to increased cardiac mortality in post-myocardial infarction patients . Whether decreased HRV is associated with endothelial dysfunction or restenosis is unknown.
Objective The objective of this study is to evaluate whether impaired endothelial function and low HRV are associated with clinical restenosis.
Furthermore, the study examines a potential correlation between biomarkers of endothelial cell activation and endothelial dysfunction.
Another issue is depression after PCI and a potential association with impaired endothelial function and increased levels of makers for endothelial activation.
Methods
Subjects This prospective study includes consecutively patients with acute coronary syndromes undergoing PCI with stent implantation for significant single vessel disease at Stavanger University Hospital, Stavanger, Norway. Patients will be followed for at least 6 months.
Exclusion criteria are multivessel disease, left ventricular dysfunction defined as ejection fraction (EF) < 50%, former aortocoronary bypass-surgery, systemic inflammatory diseases other than atherosclerosis, cognitive impairement, severe psychiatric disorder, renal failure (kreatinin > 250 mmol/l), refusion to participate.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
patients who have been revascularized by coronary intervention with stent implantation
Inclusion Criteria:
- Patients after successful revascularization by percutaneous coronary intervention with stent implantation for single coronary artery disease
Exclusion Criteria:
- Multivessel coronary artery disease
- Left ventricular dysfunction defined as ejection fraction (EF) < 50%
- Former aortocoronary bypass-surgery
- Systemic inflammatory diseases other than atherosclerosis
- inability to give informed consent
- Renal failure (kreatinin > 250 mmol/l)
- Refusion to participate
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Peter Scott Munk, MD, Stavanger University Hospital |
| ClinicalTrials.gov Identifier: | NCT00999323 History of Changes |
| Other Study ID Numbers: | 2007.061.07 |
| Study First Received: | October 20, 2009 |
| Last Updated: | October 20, 2009 |
| Health Authority: | Norway: Ethics Committee |
ClinicalTrials.gov processed this record on May 19, 2013